Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of AEZS opened at $4.64 on Tuesday. The company has a market capitalization of $8.31 million, a P/E ratio of -0.31 and a beta of 1.60. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.80. The stock has a 50-day moving average price of $7.61 and a 200 day moving average price of $7.75.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) EPS for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.